Leiomyosarcoma - Pipeline Review, H1 2019

Home/Leiomyosarcoma - Pipeline Review, H1 2019

Leiomyosarcoma - Pipeline Review, H1 2019

Drug Pipeline, Pharma & Healthcare

Publication ID:

GMD0319047

Publication Date:

March 29, 2019

Pages:

461

Publisher:

Global Markets Direct

Region:

Global

$2,000.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Leiomyosarcoma - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Pipeline Review, H1 2019, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape.

Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leiomyosarcoma - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Leiomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leiomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Unknown stages are 1, 12, 10, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Leiomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leiomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leiomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leiomyosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leiomyosarcoma - Overview
Leiomyosarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Leiomyosarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leiomyosarcoma - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
ALX Oncology Inc
Apexigen Inc
AstraZeneca Plc
BeiGene Ltd
BioMed Valley Discoveries Inc
Cell Medica Ltd
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
Incyte Corp
Karyopharm Therapeutics Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Nektar Therapeutics
Novartis AG
Ono Pharmaceutical Co Ltd
Pfizer Inc
PTC Therapeutics Inc
Vicore Pharma AB
Vicus Therapeutics LLC
Y-mAbs Therapeutics Inc
Yooyoung Pharm Co Ltd
Leiomyosarcoma - Drug Profiles
(etodolac + propranolol hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALX-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anlotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-005M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atezolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baltaleucel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bempegaldesleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
berzosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cabometyx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Carboxyamidotriazole Orotate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Epstein-Barr Virus Associated Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNV-NT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crenigacestat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nivolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pamiparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTC-596 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapanisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leiomyosarcoma - Dormant Projects
Leiomyosarcoma - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Number of Products under Development for Leiomyosarcoma, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Leiomyosarcoma - Pipeline by Advenchen Laboratories LLC, H1 2019
Leiomyosarcoma - Pipeline by ALX Oncology Inc, H1 2019
Leiomyosarcoma - Pipeline by Apexigen Inc, H1 2019
Leiomyosarcoma - Pipeline by AstraZeneca Plc, H1 2019
Leiomyosarcoma - Pipeline by BeiGene Ltd, H1 2019
Leiomyosarcoma - Pipeline by BioMed Valley Discoveries Inc, H1 2019
Leiomyosarcoma - Pipeline by Cell Medica Ltd, H1 2019
Leiomyosarcoma - Pipeline by Eli Lilly and Co, H1 2019
Leiomyosarcoma - Pipeline by Exelixis Inc, H1 2019
Leiomyosarcoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Leiomyosarcoma - Pipeline by Incyte Corp, H1 2019
Leiomyosarcoma - Pipeline by Karyopharm Therapeutics Inc, H1 2019
Leiomyosarcoma - Pipeline by MedImmune LLC, H1 2019
Leiomyosarcoma - Pipeline by Merck & Co Inc, H1 2019
Leiomyosarcoma - Pipeline by Merck KGaA, H1 2019
Leiomyosarcoma - Pipeline by Nektar Therapeutics, H1 2019
Leiomyosarcoma - Pipeline by Novartis AG, H1 2019
Leiomyosarcoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2019
Leiomyosarcoma - Pipeline by Pfizer Inc, H1 2019
Leiomyosarcoma - Pipeline by PTC Therapeutics Inc, H1 2019
Leiomyosarcoma - Pipeline by Vicore Pharma AB, H1 2019
Leiomyosarcoma - Pipeline by Vicus Therapeutics LLC, H1 2019
Leiomyosarcoma - Pipeline by Y-mAbs Therapeutics Inc, H1 2019
Leiomyosarcoma - Pipeline by Yooyoung Pharm Co Ltd, H1 2019
Leiomyosarcoma - Dormant Projects, H1 2019
Leiomyosarcoma - Discontinued Products, H1 2019

List of Figures
List of Figures
Number of Products under Development for Leiomyosarcoma, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Companies Covered

Advenchen Laboratories LLC
ALX Oncology Inc
Apexigen Inc
AstraZeneca Plc
BeiGene Ltd
BioMed Valley Discoveries Inc
Cell Medica Ltd
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
Incyte Corp
Karyopharm Therapeutics Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Nektar Therapeutics
Novartis AG
Ono Pharmaceutical Co Ltd
Pfizer Inc
PTC Therapeutics Inc
Vicore Pharma AB
Vicus Therapeutics LLC
Y-mAbs Therapeutics Inc
Yooyoung Pharm Co Ltd

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".